

Name of the Issuer:		Global Health Limited	Last updated on	15-Nov-23												
1	Type of Issue (IPO / FPO)		IPO													
	Source: Prospectus dated November 09, 2022															
2	Issue Size (Rs. Million)*		22,055.70													
	- Fresh Issue Size (Rs. Millions)		5,000.00													
	- Offer for Sale Component (Rs. Millions)		17,055.70													
	*Source: Final post issue report dated November 17, 2022 and Prospectus dated November 09, 2022															
3	Grade of issue along with name of the rating agency															
	Name		Not Applicable													
	Grade		Not Applicable													
	Source: Prospectus dated November 09, 2022															
4	Subscription Level (Number of times)		7.11*													
	*Source: Final post issue report dated November 17, 2022															
	*The above figure is after technical rejections and including Anchor Investors															
5	QIB Holding (as a % of outstanding capital) as disclosed to stock exchanges															
	<table><tr><th>Particulars</th><th>%</th></tr><tr><td>(i) allotment in the issue⁽¹⁾</td><td>14.54%</td></tr><tr><td>(ii) at the end of 1st Quarter immediately after the listing (December 31, 2022)⁽¹⁾</td><td>21.90%</td></tr><tr><td>(iii) at the end of 1st FY (March 31, 2023)⁽¹⁾</td><td>22.24%</td></tr><tr><td>(iv) at the end of 2nd FY (March 31, 2024)*</td><td>Not Available</td></tr><tr><td>(v) at the end of 3rd FY (March 31, 2025)*</td><td>Not Available</td></tr></table>				Particulars	%	(i) allotment in the issue ⁽¹⁾	14.54%	(ii) at the end of 1st Quarter immediately after the listing (December 31, 2022) ⁽¹⁾	21.90%	(iii) at the end of 1st FY (March 31, 2023) ⁽¹⁾	22.24%	(iv) at the end of 2nd FY (March 31, 2024)*	Not Available	(v) at the end of 3rd FY (March 31, 2025)*	Not Available
Particulars	%															
(i) allotment in the issue ⁽¹⁾	14.54%															
(ii) at the end of 1st Quarter immediately after the listing (December 31, 2022) ⁽¹⁾	21.90%															
(iii) at the end of 1st FY (March 31, 2023) ⁽¹⁾	22.24%															
(iv) at the end of 2nd FY (March 31, 2024)*	Not Available															
(v) at the end of 3rd FY (March 31, 2025)*	Not Available															
	*QIB Holding not disclosed as reporting for the relevant period / fiscal year has not been completed.															
	(1) Source: Reporting with the BSE. Represents holding of Institutions category															
6	Financials of the issuer															
	(In Rs. Millions)															
	Parameters	1st FY (March 31, 2023) ⁽¹⁾	2nd FY (March 31, 2024)*	3rd FY (March 31, 2025)*												
	Income from Operations	26942.48	Not Available	Not Available												
	Net Profit for the period	3260.79	Not Available	Not Available												
	Paid-up equity share capital	536.39	Not Available	Not Available												
	Reserves excluding revaluation reserves	23745.69	Not Available	Not Available												
	(1)Financial Statements for FY 2022-23 submitted with BSE															
	*Financials not disclosed as reporting for the relevant fiscal year has not been completed.															
7	Trading Status in the scrip of the issuer															
	Company's Equity Shares are listed on both BSE Limited and National Stock Exchange of India Limited															
	The Shares have not been suspended or delisted.															
	<table><tr><th>Particulars</th><th>Status</th></tr><tr><td>(i) at the end of 1st FY (March 31, 2023)</td><td>Frequently Traded</td></tr><tr><td>(ii) at the end of 2nd FY (March 31, 2024)*</td><td>Not Available</td></tr><tr><td>(iii) at the end of 3rd FY (March 31, 2025)*</td><td>Not Available</td></tr></table>				Particulars	Status	(i) at the end of 1st FY (March 31, 2023)	Frequently Traded	(ii) at the end of 2nd FY (March 31, 2024)*	Not Available	(iii) at the end of 3rd FY (March 31, 2025)*	Not Available				
Particulars	Status															
(i) at the end of 1st FY (March 31, 2023)	Frequently Traded															
(ii) at the end of 2nd FY (March 31, 2024)*	Not Available															
(iii) at the end of 3rd FY (March 31, 2025)*	Not Available															
	*Trading status not disclosed as the relevant fiscal year has not been completed.															
8	Change in Directors of issuer from the disclosures in the offer document															
	<table><tr><th>Particulars</th><th>Name of the Director</th><th>Appointed / Resigned</th></tr><tr><td>(i) at the end of 1st FY (March 31, 2023)</td><td>Pankaj Sahni</td><td>Appointment as Whole-time Director</td></tr><tr><td>(ii) at the end of 2nd FY (March 31, 2024)*#</td><td>Nil</td><td>Not Applicable</td></tr><tr><td>(iii) at the end of 3rd FY (March 31, 2025)*</td><td>Not Available</td><td>Not Available</td></tr></table>				Particulars	Name of the Director	Appointed / Resigned	(i) at the end of 1st FY (March 31, 2023)	Pankaj Sahni	Appointment as Whole-time Director	(ii) at the end of 2nd FY (March 31, 2024)*#	Nil	Not Applicable	(iii) at the end of 3rd FY (March 31, 2025)*	Not Available	Not Available
Particulars	Name of the Director	Appointed / Resigned														
(i) at the end of 1st FY (March 31, 2023)	Pankaj Sahni	Appointment as Whole-time Director														
(ii) at the end of 2nd FY (March 31, 2024)*#	Nil	Not Applicable														
(iii) at the end of 3rd FY (March 31, 2025)*	Not Available	Not Available														
	Source: Stock Exchnage Filings															
	* Changes in Directors not disclosed as the relevant fiscal year has not been completed.															
	# Updated as on the last track record date															

9	Status of implementation of project/ commencement of commercial production	
(i) as disclosed in the offer document	Not Applicable	
(ii) Actual implementation	Not Applicable	
(iii) Reasons for delay in implementation, if any	Not applicable	

10

Status of utilization of issue proceeds

(i) as disclosed in the offer document

Utilization of the proceeds of the Fresh Issue

Particulars	Amount (in ₹ million)
Gross proceeds of the Fresh Issue	5,000.00
Less Issue related expenses	232.99
Net Proceeds	4,767.01

Utilisation of the Net Proceeds (in ₹ million)

Particulars	Total estimated amount/cost	Estimated Utilization of Net Proceeds in FY 2023
Investment in two of our Subsidiaries, GHPPL and MHPL, in the form of debt or equity for repayment / prepayment of borrowings, in full or part, of such Subsidiaries	3,750.00	3,750.00
General corporate purposes	1,017.01	1,017.01
Total	4,767.01	4,767.01

Source: Prospectus dated November 09, 2022

(ii) Actual utilization

Utilisation of the Net Proceeds (in ₹ million)

Particulars	Amount to be deployed from Net Proceeds	Amount deployed/utilized as at September 30, 2023*	Amount unutilized as at September 30, 2023*
Investment in two of our Subsidiaries, GHPPL and MHPL, in the form of debt or equity for repayment / prepayment of borrowings, in full or part, of such Subsidiaries	3,750.00	3,750.00	-
General corporate purposes	1,017.01	472.47	544.54
Total	4,767.01	Nil	544.54

* Monitoring Agency Report dated November 9, 2023

(iii) Reasons for deviation, if any

Not applicable

11	Comments of monitoring agency	
(a) Comments on use of funds	None*	
(b) Comments on deviation, if any, in the use of proceeds of the issue from the objects stated in the offer document		
(c) Any other reservations expressed by the monitoring agency about the end use of funds		
* Monitoring Agency Report dated November 9, 2023		

12 Pricing Data

Issue Price (Rs.):

336

Designated Stock Exchange:

NSE

Listing Date:

16-Nov-22

Price parameters	At close of listing day (November 16, 2022)	At close of 30th calendar day from listing day (December 15, 2022) ⁽¹⁾	At close of 90th calendar day from listing day (February 13, 2023) ⁽²⁾	As at the end of 1st FY after the listing of the issue (March 31, 2023) ⁽³⁾		
				Closing price	High (during the FY)	Low (during the FY)
Market Price on Designated Stock Exchange ⁽⁵⁾	415.30	447.65	456.75	526.95	538.00	390.55
NIFTY 50 ⁽⁵⁾	18,409.65	18,414.90	17,770.90	17,359.75	18,887.60	15,183.40
Sectoral Index ⁽⁶⁾	Not Applicable			Not Applicable		

Price parameters	As at the end of 2nd FY after the listing of the issue (March 31, 2024) ⁽³⁾⁽⁴⁾			As at the end of 3rd FY after the listing of the issue (March 31, 2025) ^{(3) (4)}		
	Closing price	High (during the FY)	Low (during the FY)	Closing price	High (during the FY)	Low (during the FY)
Market Price on Designated Stock Exchange ⁽⁵⁾	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available
NIFTY 50 ⁽⁵⁾	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available
Sectoral Index ⁽⁶⁾	Not Applicable			Not Applicable		

Source: NSE website

Note:

(1) 30th calendar day shall be taken as listing date plus 29 calendar days.

(2) 90th calendar day shall be taken as listing date plus 89 calendar days.

(3) High and Low based on intra day prices

(4) Pricing data not disclosed as the relevant period/ fiscal year has not completed

(5) In case of any reporting day falling on a holiday, previous trading day prices/values have been disclosed.

(6) Comparable Sectoral index is not available

13 Basis for Issue Price

Accounting ratio	As disclosed in the offer document ⁽¹⁾	At the end of 1st FY (March 31, 2023) ⁽²⁾	At the end of 2nd FY (March 31, 2024) ⁽³⁾	At the end of 3rd FY (March 31, 2025) ⁽³⁾
EPS	Issuer:			
	Consolidated (Basic)	7.78	12.58	Not Available
	Consolidated (Diluted)	7.77	12.57	Not Available
	Peer Group: (Consolidated)			
	Apollo Hospitals Enterprises Limited	73.42	56.97	Not Available
	Fortis Healthcare Limited	7.35	7.80	Not Available
	Max Healthcare Insitute Limited	6.24	11.36	Not Available
	Narayana Hrudayalaya Limited	16.84	29.85	Not Available
	Industry Avg:	25.96	26.50	N.A.
Revenue from Operations (Rs. Million)	Issuer:			
	Consolidated (Diluted)	22,058.17	26,942.48	Not Available
	Peer Group: (Consolidated)			
	Apollo Hospitals Enterprises Limited	147408.00	167,027.90	Not Available
	Fortis Healthcare Limited	57449.48	63,593.50	Not Available
	Max Healthcare Insitute Limited	40588.20	47,018.40	Not Available
	Narayana Hrudayalaya Limited	37358.76	45,247.65	Not Available
	Industry Avg:	70701.11	80721.86	N.A.
Price to Earnings Ratio (P/E)	Issuer:			
	Consolidated (Diluted)	43.24	41.86	Not Available
	Peer Group: (Consolidated)			
	Apollo Hospitals Enterprises Limited	59.44	75.64	Not Available
	Fortis Healthcare Limited	39.11	33.33	Not Available
	Max Healthcare Insitute Limited	73.24	38.82	Not Available
	Narayana Hrudayalaya Limited	43.82	25.93	Not Available
	Industry Avg:	53.90	43.43	N.A.

RoNW(%)	Issuer:				
	Consolidated	12.14	13.43	Not Available	Not Available
	Peer Group: (Consolidated)				
	Apollo Hospitals Enterprises Limited	18.86	13.65	Not Available	Not Available
	Fortis Healthcare Limited	11.27	8.74	Not Available	Not Available
	Max Healthcare Insitute Limited	9.63	14.89	Not Available	Not Available
	Narayana Hrudayalaya Limited	22.97	28.46	Not Available	Not Available
	Industry Avg:	15.68	16.44	N.A.	N.A.
NAV per Equity Share	Issuer:				
	Consolidated	63.82	90.54	Not Available	Not Available
	Peer Group: (Consolidated)				
	Apollo Hospitals Enterprises Limited	408.78	430.46	Not Available	Not Available
	Fortis Healthcare Limited	92.83	95.93	Not Available	Not Available
	Max Healthcare Insitute Limited	64.79	76.31	Not Available	Not Available
	Narayana Hrudayalaya Limited	72.88	104.30	Not Available	Not Available
	Industry Avg:	159.82	176.75	N.A.	N.A.
Notes: (1) Sourced from Prospectus dated November 09, 2022. (2) Information sourced from financials filed by the Issuer Company and Peers on the stock exchanges (3) Information not provided as the relevant fiscal year has not completed Key ratios for the Company for the three fiscal years stated above shall be calculated as follows: (i) Basic Earnings per Share (Rs.) = net profit after tax and adjustments, attributable to equity shareholders / Weighted average no. of equity shares outstanding during the fiscal year. Earnings per share calculations are in accordance with the notified Ind AS 33 'Earnings per share' notified accounting standard by the Companies (Indian Accounting Standards) Rules of 2015 (as amended). (ii) Diluted Earnings per Share (Rs.) = net profit after tax and adjustments, attributable for equity shareholders (after adjusting profit impact of dilutive potential equity shares, if any) / the aggregate of weighted average number of Equity shares outstanding during the year and the weighted average number of Equity shares that would be issued on conversion of all the dilutive potential Equity shares into Equity shares. (iii) Total Income = Revenue from Operations and Other Income (iv) P/E (Basic/Diluted) - Closing Market Price et the end of relevant fiscal year end on NSE/ Basic/Diluted EPS (v) Return on Net Worth (%) = Net profit after tax, available for equity shareholders / Net worth at the end of the fiscal year. (vi) Net Asset Value per Equity Share = Net worth at the end of the fiscal year./ Number of equity shares outstanding as at the end of fiscal year					

14 Any other material information

Date of disclosure	Announcement
16-Nov-22	Listing of equity shares of Electronics Mart India Ltd
17-Nov-22	Submission of Details Of Key Managerial Personnel Under Regulation 30(5) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 Of Global Health Limited ("The Company")
16-Dec-22	Submission of copy of investor presentation
22-Dec-22	Submission of outcome of the Board Meeting approving (i) Amendment in Articles of Association of the Company (ii) Appointment of Mr. Pankaj Prakash Sahni (DIN:07132999) as Additional Director and Whole Time Director, for a period of Five (5) Years with effect from 1st January, 2023 and (iii) Ratification of ESOP 2016 Scheme and ESOP 2021 Scheme of the Company.
26-Dec-22	Submission of a copy of Postal Ballot Notice dated 22nd December, 2022 along with the Explanatory Statement, for seeking approval of the Members
28-Dec-22	Submission of the copies of Newspaper clippings of the advertisement published in Financial Express (English) and Jansatta (Hindi) on Wednesday, 28th December, 2022 regarding completion of dispatch of Postal Ballot Notice
17-Nov-22	Submission of Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
5-Jan-23	Submission of Code Of Practices And Procedures For Fair Disclosure Of Unpublished Price Sensitive Information
30-Jan-23	Submission of 1) Voting results in compliance with Regulation 44(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015; and 2) Consolidated Scrutinizer"s Report dated January 30, 2023 issued by Mr. Mukesh Kumar Agarwal (M. No. F-5991; C.P.No.:3851) Proprietor of Mukesh Agarwal & Co., Practicing Company Secretaries
4-Feb-23	Board Meeting Intimation for Inter Alia, To Consider And Approve The Unaudited Financial Results Of The Company For The Quarter And Nine Months Ended December 31, 2022.
13-Feb-23	Outcome Of Board Meeting - approved Unaudited Standalone and Consolidated Financial Results of the Company for the Quarter and Nine months ended December 31, 2022 (Results) and approved The binding term sheet for a new hospital at Indore on Operation & Management basis.
13-Feb-23	Submission of press release - Unaudited Standalone and Consolidated Financial Results of the Company for the Quarter and Nine months ended December 31, 2022 and the binding term sheet for a new hospital at Indore on Operation & Management basis
13-Feb-23	Submission of opy of Investor Presentation for the Quarter III & Nine Months ended December 31, 2022 financial results of the Company
13-Feb-23	Submission of the Monitoring Agency Report, towards utilization of proceeds of Initial Public Offer of the Company for the quarter ended December 31, 2022, issued by CRISIL Ratings Limited
14-Feb-23	Submission of the copies of Newspaper clippings of the Unaudited Financial Results of the Company for the Quarter III and nine months ended December 31, 2022, published in Financial Express (English) and Jansatta (Hindi) on Tuesday, 14th February, 2023.

20-Feb-23	Submission of link of transcript of Earnings Conference Call held on Tuesday, February 14, 2023, for the Quarter III & Nine Months ended December 31, 2022 Results of the Company.
17-Mar-23	The Company has allotted 10,290 Equity Shares of face value of Rs. 2/- each to 1 (One) eligible employee upon exercise of options vested under ESOP 2016 Scheme. Consequent to the aforesaid allotment, the paid-up share capital of the Company has increased from 26,81,84,882 equity shares to 26,81,95,172 equity shares.
27-Mar-23	Outcome of Board meeting - the Company has approved the binding Term Sheet for a new hospital at Indore on Operation & Management basis.
10-Apr-23	Submission of the Certificate dated April 6, 2023, received from the Registrar and Transfer Agent of the Company i.e. Kfin Technologies Limited, w.r.t. compliance under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the Quarter ended March 31, 2023.
10-Apr-23	Submission of the Compliance Certificate under Regulation 7(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the year ended March 31, 2023, duly signed by the Compliance Officer of the Company and Authorized Representative of Kfin Technologies Limited, the Registrar and Share Transfer Agent of the Company
15-Apr-23	Submission of the Certificate for the period from November 16, 2022 (i.e. the date of listing of Equity Shares of the Company) to March 31, 2023, received from Practicing Company Secretary, i.e. M/s Mukesh Agarwal & Co; in respect of compliance under Regulation 40(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
26-Apr-23	Submission of the Annual Secretarial Compliance Report, for the Financial Year 2022-23, issued by M/s VAPN & Associates, Practicing Company Secretaries.
27-Apr-23	Submission of the details in format of the Initial Disclosure to be made by an entity identified as a Large Corporate.
11-May-23	Submission of the Monitoring Agency Report, towards utilization of proceeds of Initial Public Offer of the Company for the quarter ended March 31, 2023, issued by CRISIL Ratings Limited.
27-May-23	Submission of Audited Standalone And Consolidated Financial Results Of The Company For The Quarter And Financial Year Ended March 31, 2023
27-May-23	Board Meeting Outcome for Outcome Of Board Meeting Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 ('Listing Regulations') - considered and approved the following: 1) Audited Standalone and Consolidated Financial Results of the Company for the Quarter and Financial Year ended March 31, 2023. ('Results'). The Certified copies of Results along with Audit Reports from the Statutory Auditors of the Company and Declaration on Auditor's Report with unmodified opinion pursuant to Regulation 33(3) (d) of Listing Regulations read with SEBI circular No. CIR/CFD/CMD/56/2016, dated May 27, 2016 are enclosed herewith. 2) Allotment of 9,710 Equity Shares of face value of Rs. 2/- each to 1 (One) eligible employee upon exercise of options vested under ESOP 2016 Scheme
27-May-23	Submission of the Nil Statement Of Deviation/Variation In Utilization Of Funds Raised Through Initial Public Offer ('IPO')
27-May-23	Submission of the disclosure of Related Party Transactions for the half year ended March 31, 2023, the copy of Investor Presentation for Investors, on the Financial Results of the Company for the Quarter and Financial Year ended March 31, 2023, the Press Release on the Financial Results of the Company for the Quarter and Financial Year ended March 31, 2023
27-May-23	Allotment - approved the Allotment of 9,710 Equity Shares of face value of Rs. 2/- each to 1 (One) eligible employee upon exercise of options vested under ESOP 2016 Scheme. Consequent to the aforesaid allotment, the paid-up share capital of the Company has increased from Rs. 53,63,90,344/- to Rs. 53,64,09,764/-. In terms of Regulation 10(c) of the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021
27-May-23	Submission of the Key Performance Indicators (KPIs) for FY 2022-23.
28-May-23	Submission of the copies of Newspaper clippings of the Financial Results, for the Quarter & Financial Year ended March 31, 2023, published in Financial Express (English) and Jansatta (Hindi) on Sunday, 28th May, 2023.
29-May-23	Submission of the link of Audio recording of Earnings Conference Call held on Monday, May 29, 2023 hosted by Motilal Oswal , for the Quarter & Financial Year ended March 31, 2023
3-Jun-23	Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the transcript of the Earnings Conference Call held on Monday, May 29, 2023, hosted by Motilal Oswal, for the Quarter & Financial Year ended March 31, 2023 is
26-Jun-23	The Stakeholder Relationship Committee of the Company on June 21, 2023 vide Resolution passed by circulation has allotted 62,500 Equity Shares of face value of Rs. 2/- each to 1 (One) eligible employee upon exercise of options vested under ESOP 2016 Scheme.
28-Jun-23	In continuation of our letters dated 13th February, 2023 and 27th March, 2023, regarding binding term sheet for a new hospital at Indore (Term Sheet) on Operation & Management Basis, we would like to inform you that due diligence and finalization of terms of final agreement is still in process. As such, the Term Sheet is now non-binding in nature
10-Jul-23	Submission of Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
24-Jul-23	Allotment of 73,000 Equity Shares under ESOP 2016 Scheme.
1-Aug-23	Global Health Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2023 ,inter alia, to consider and approve the Unaudited Financial Results of the Company for the quarter ended 30th June, 2023
9-Aug-23	Allotment of 20,000 Equity Shares under Global Health Limited -ESOP 2016 Scheme

10-Aug-23	Outcome of the Board Meeting - Unaudited Standalone and Consolidated Financial Results of the Company for the First Quarter ended June 30, 2023 ('Results'); and 2. To Convene the 19th Annual General Meeting of the Company to be held on Wednesday, September 20, 2023, at 12 Noon through Video Conferencing/Other Audio Video Means ('VC/OAVM') Facility. In addition, the Board has also approved a Binding Term Sheet with DLF Limited ('DLF') wherein a Special Purpose Vehicle ('SPV') will be incorporated by GHL, to set up approx. 400 bed multi-speciality hospital in Delhi. The Proposed SPV shall be a Public Limited Company and have 50:50 Equity Shareholding of the GHL and DLF
10-Aug-23	Submission of Statement Of Deviation/Variation In Utilization Of Funds Raised Through Initial Public Offer ('IPO') and Investor Presentation for the quarter ended June 30, 2023 Results of the Company
10-Aug-23	Submission of press release -Joint Press Release titled " Medanta and DLF" to develop a 400 bed multi-speciality hospital in Delhi and Press Release for the quarter ended June 30, 2023 Results of the Company
11-Aug-23	Submission of Newspaper Publication for June 30, 2023 Results of the Company and Monitoring Agency Report for quarter ended June 30, 2023 and Audio Recording Link of Earning Conference Call held on Friday, August 11, 2023 hosted by JM Financial.
17-Aug-23	Submission of guidelines for materiality referred in Regulation 30 (4) of the Listing Regulations
18-Aug-23	Allotment of 40,000 Equity Shares under ESOP 2016 Scheme.
18-Aug-23	Submission of Transcript of Earning Conference Call held on Friday, 11 August, 2023.
21-Aug-23	Submission of Investor Presentation made at Motilal Oswal 19th Annual Global Investor Conference, 2023.
22-Aug-23	Submission of Newspaper Publication for conducting the 19th AGM of the Company by VC/OAVM.
23-Aug-23	Mr. Manoj Gupta, SVP and Head HR, of our Company has resigned today and his resignation was accepted. September 02, 2023 will be his last working day.
25-Aug-23	Submission of Annual Report of the Company for FY 2022-23, Notice Of The 19Th Annual General Meeting Of The Company Scheduled To Be Held On 20Th September, 2023. and Business Responsibility and Sustainability Reporting (BRSR)
28-Aug-23	Pursuant to provisions of Regulation 30 and 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith copies of Newspaper Advertisement post dispatch of AGM Notice.
11-Sep-23	Mr. Saurabh Upadhyay has been appointed as Senior Managerial Personnel, designated as 'Senior Vice President & Head - Human Resources' of the Company.
19-Sep-23	Allotment of 7,000 Equity Shares pursuant to exercise of ESOPs under Global Health Limited - ESOP 2016 Scheme.
20-Sep-23	Proceedings of the 19th Annual General Meeting of Global Health Limited, held on September 20, 2023.
21-Sep-23	Submission of Voting Results and Consolidated Scrutinizer"s Report of the 19th AGM of the Company.
11-Oct-23	Submission of Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
26-Oct-23	Allotment of 20,000 Equity Shares, on exercise of ESOPs under ESOP 2016 Scheme.
30-Oct-23	Board Meeting Intimation for Consider And Approve The Unaudited Financial Results Of The Company For The Quarter And Half Year Ended 30Th September, 2023.
9-Nov-23	he Board of Directors of Global Health Limited ('GHL/Company') at its meeting held today i.e. Thursday, November 9, 2023, inter-alia, has approved the Unaudited Standalone and Consolidated Financial Results of the Company for the Quarter and Half year ended September 30, 2023 ('Results'). The certified copies of Results along with Limited Review Reports from the Statutory Auditors M/s Walker Chandiok & Co LLP, Chartered Accountants thereon, are enclosed herewith as Exhibit, Further, in continuance with our earlier intimation dated August 10, 2023, Re. development of a 400 bed multi-specialty hospital in Delhi along with M/s DLF Limited, please note that, the Board of Directors of the Company at its meeting held today has approved execution of definitive agreement for jointly incorporation of Special Purpose Vehicle (SPV) with M/s DLF Limited.
9-Nov-23	Submission of Nil Statement Of Deviation/Variation In Utilization Of Funds Raised Through Initial Public Offer ('IPO') For The Quarter Ended September 30, 2023
9-Nov-23	The Board of Directors of the Company at its meeting held today i.e. November 9, 2023 has approved execution of definitive agreements along with other necessary papers for jointly incorporation of Special Purpose vehicle with M/s DLF Limited. Special Purpose Company to be incorporated jointly by DLF Limited and GHL, in which both companies will have 50.50 Equity Shareholding.
9-Nov-23	Submission of Press Release for Second Quarter and Half year ended Sep 30, 2023, Investor Presentation for Quarter and Half Year Ended September 30, 2023 Results of the Company.
10-Nov-23	Submission of Monitoring Agency Report for the quarter ended September 30, 2023.

10-Nov-23	Submission of Newspaper Publication for Unaudited Financial Results of the Company for the Quarter and Half year ended September 30, 2023.
-----------	--

Soure: Filings with BSE

Note: The Company meets Investors/ Analysts/ Participants from time to time. Please refer to the website of the Stock Exchanges for the intimation of the schedule of such meetings and related details, as applicable.
For further updates and information, please refer to the website of the Stock Exchanges i.e. www.bseindia.com and / or www.nseindia.com.

Disclaimer:

The information compiled herein is in accordance with the disclosure requirements with regard to the track record of the public issues managed by JM Financial Limited ("JM Financial") arising out of the SEBI Circular No. CIR/MIRSD/1/2012 dated January 10, 2012.

This information is gathered, inter-alia, from the Prospectus of the Issuer, as amended, and from the filings made by the Issuer with the BSE Limited ("BSE") and / or the National Stock Exchange of India Limited ("NSE" and together with the BSE, the "Stock Exchanges") from time to time, price-volume data available on the website of the Stock Exchanges, other sources as disclosed herein and information / clarifications provided by the Issuer.

Nothing in this information is intended by JM Financial to be construed as legal, regulatory, accounting, tax or other advice. While reasonable care has been taken to ensure that the information provided herein is accurate and is taken from the sources that we believe are reliable, the user of this information may independently verify the accuracy of the information before taking any decision based on the above information.

Notwithstanding the above, JM Financial does not make any express or implied representation or warranty as to the authenticity, accuracy or completeness of the information or data contained herein and shall not be liable in any manner for the same. Neither JM Financial nor any of its affiliates or their directors, officers and employees will be responsible or be liable for any loss or damage including any loss of profits incidental or consequential damage, howsoever arising, suffered or incurred by any person accessing and / or using this information. The person accessing and utilizing the information is accordingly once again advised to independently verify the information and satisfy himself about the adequacy, accuracy and completeness for his specific requirement. JM Financial does not undertake to update the information contained herein except as required by applicable law or regulation.